Welcome to MedInsight® A nonprofit medical research organization with a single focus:
Creating Life-Saving Knowledge. For Everyone.
If a treatment for a disease exists - but no one hears about it, how can it make a difference?
MedInsight is a non-profit research organization dedicated to delivering fresh and impactful treatment opportunities via free access to uncommercialized medical discoveries.
Our mission is to empower patients and physicians to leave no stone unturned when seeking treatment options for challenging diagnoses and conditions with unmet medical needs.
We achieve our goal in the following ways:
In-depth data-mining and analysis of the 2.5 Million research papers published annually to illuminate unpublicized scientifically-proven treatment opportunities.
Indexing MedInsight’s findings, therapeutic options that have no commercial sponsorship, in our proprietary database Cureiosity®.
Converting scientific medical literature such as published articles in medical journals, clinical research, and trial outcomes, into digestible and accessible treatment opportunities.
Creating and maintaining web and social platforms that deliver timely information to physicians, patients, and caregivers.
We achieve our goal in the following ways:
Transforming information into knowledge
Medical research has rapidly grown over the past 50 years. These scientific efforts now produce over 40,000 new research articles each week. The flood of valuable information creates an increasingly difficult challenge: converting all this valuable information into actionable knowledge. However, extracting immediately-actionable knowledge is critical for delivering safe and precise solutions to complex medical situations.
Placing knowledge at your fingertips
MedInsight’s research teams work relentlessly to extract practical knowledge from the thousands of new research papers published each day, collate this knowledge in a user-friendly manner, and disseminate it to physicians and patients using a variety of platforms. MedInsight seeks to place this knowledge at the fingertips of every physician and patient in order to provide immediate answers for every unmet medical need.
Putting the patient first - focusing on overlooked treatments
MedInsight’s researchers place their focus on therapeutic options that have no commercial sponsorship. Less than 5% of all available medications benefit from pharmaceutical companies’ educational activities. As a not-for-profit organization, MedInsight augments these efforts by making knowledge about unpromoted medications available to everyone, placing the patient’s interest at the forefront.
Yesterday’s Medicines - Today’s Cures
MedInsight drives innovation in healthcare by harnessing the untapped knowledge about tens of thousands of currently available medications. Our methodologies include:
- Performing in-depth data-mining and analysis of the medical literature and extracting actionable knowledge.
- Indexing this knowledge in our cutting-edge Cureiosity® database.
- Compiling and publishing comprehensive review articles in the medical literature.
- Initiating, supporting, and participating in studies that identify new ways to use existing medications.
- Creating educational materials and videos about novel uses of existing medications.
- Maintaining web-platforms that deliver timely knowledge to physicians, researchers, and patients.
Low Dose Naltrexone (LDN), a breakthrough treatment for chronic and autoimmune diseases, helps over 300,000 patients worldwide. LDNscience.org, by MedInsight, is the most authoritative and up-to-date source of information about LDN. It houses the entire collection of LDN research and scientific studies; interviews with scientists, physicians and patients; a free global LDN prescriber directory; and frequently asked questions.
Dipyridamole, a cardiovascular drug that has been in use for over 50 years, has been rediscovered as a powerful treatment for a number of difficult-to-treat eye disorders. EyeDipyridamole.org, by MedInsight, is the most current source of information about the use of dipyridamole for eye disorders. It houses all available research and scientific studies, interviews with researchers and patients, frequently asked questions, and the latest news about this novel eye treatment.
Cureiosity® is a repository of manually curated knowledge about novel treatments for serious, chronic, and intractable diseases. The knowledge is created by data-scientists who analyze global medical literature and catalogue the information they extract. They do this in a proprietary manner using a next-generation graph-database. Cureiosity® places patients’ interests first by focusing on overlooked treatments that don’t benefit from commercial sponsorship.
David A. Youlton
Co-founder, MedInsight Research Institute
David Youlton was a visionary British business leader and public activist. Diagnosed with advanced prostate cancer in 2000 at the age of 56, David refused to accept his grim prognosis and sought out personalized medical treatment under the direction of Moshe Rogosnitzky. Following his own motto, “Overcoming the Pessimism of the Intellect with the Optimism of the Will”, David outlived his grim prognosis and survived another seven years, maintaining his usual activities throughout the challenges he faced. In line with his visionary attitude, infallible optimistic spirit and generosity, David co-founded the MedInsight Research Institute in 2006, with the goal of sharing life-saving information enabling patient access to novel treatments, freely and openly with all those in need.
Co-founder, Executive Director, MedInsight Research Institute
Moshe Rogosnitzky is a research scientist, inventor, and medical innovator. An esteemed consultant to oncology specialists, patients, and companies, Moshe delivers “outside the box” medical solutions powered by his relentless medical research, passionate consumption of knowledge, and belief that medicine and science should deliver rapid and tangible benefits to the patient. Moshe’s extensive career has spanned multiple disciplines and resulted in groundbreaking cancer and autoimmune disease treatments.